HCPLive

Study Assesses Glucose Monitoring Trends in Tweens

Thursday, April 12 (HealthDay News) -- To determine whether adherence and glycemic control change during the transition to adolescence, Joseph R. Rausch, Ph.D., of the Cincinnati Children's Hospital Medical Center, and colleagues conducted a two-year longitudinal study involving 225 children aged 9 to 11 years with type 1 diabetes.

The researchers found that, over the duration of this two-year study, blood glucose monitoring frequency (BGMF) significantly decreased, from 4.9 to 4.5 checks per day, which correlated with a significant increase in HbA1c, from 8.2 to 8.6 percent. The researchers calculated that just one less check of blood glucose per day resulted in an increase in HbA1c of 1.26 percent.

"The magnitude of the effect of declining treatment adherence (BGMF) on glycemic control in young adolescents may be even greater than declines observed among older adolescents. BGMF offers a powerful tool for targeted management of glycemic control for type 1 diabetes during the critical transition to adolescence," the authors write.

Abstract
Full Text (subscription or payment may be required)

During the transition to adolescence, children with type 1 diabetes monitor their blood glucose less frequently, resulting in significant increases in HbA1c levels, according to research published online April 3 in Diabetes Care.

Copyright © 2012 HealthDay. All rights reserved.

Most Popular

Recommended Reading

Children who develop progressive familial intrahepatic cholestasis Type II (PFIC-II) may get better—at least for a while—without getting a liver transplant. But children borne with the condition do not, a team from Belgium found. Bile salt export pump plays a key role.
Diagnosing Anti-N-methyl D-aspartate receptor (NMDAR) antibody encephalitis in adults differs from doing so in young children. Gait disturbance is a reliable sign, a Johns Hopkins team reports.
A common concern of expectant parents is what can increase the likelihood of their children being diagnosed with autism. A recent study found a link between exposure to gestational diabetes and autism risk.
Soligenix, Inc., a late-stage biopharmaceutical company, recently announced that the US Food and Drug Administration (FDA) authorized a pivotal Phase 3 clinical trial to assess the efficacy of novel drug SGX203, a pediatric Crohn’s disease (CD) therapy.
$vAR$